High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1β in osteoarthritic synoviocytes.
BACKGROUND
High mobility group box 1 (HMGB1) is released by necrotic cells or secreted in response to inflammatory stimuli. Extracellular HMGB1 may act as a pro-inflammatory cytokine in rheumatoid arthritis. We have recently reported that HMGB1 is released by osteoarthritic synoviocytes after activation with interleukin-1beta (IL-1β) The present study investigated the role of HMGB1 in synovial inflammation in osteoarthritis (OA).


METHODS
HMGB1 was determined in human synovium using immunohistochemistry, comparing normal to OA. OA synoviocytes were incubated with HMGB1 at 15 or 25 ng/ml in the absence or presence of IL-1β (10 ng/ml). Gene expression was analyzed by quantitative PCR and protein expression by Western Blot and ELISA. Matrix metalloproteinase (MMP) activity was studied by fluorometric procedures and nuclear factor (NF)-κB activation by transient transfection with a NF-κB-luciferase plasmid.


RESULTS
In the normal synovium, HMGB1 was found in the synovial lining cells, sublining cells, and in the vascular wall cells. The distribution of HMGB1 in OA synovium was similar but the number of HMGB1 positive cells was higher and HMGB1 was also present in infiltrated cells. In normal synovial membrane cells, HMGB1 was found mostly in the nuclei, whereas in OA, HMGB1 was generally found mostly in the cytoplasm. In OA synoviocytes, HMGB1 alone at concentrations of 15 or 25 ng/ml did not affect the production of IL-6, IL-8, CCL2, CCL20, MMP-1 or MMP-3, but in the presence of IL-1β, a significant potentiation of protein and mRNA expression, as well as MMP activity was observed. HMGB1 also enhanced the phosphorylated ERK1/2 and p38 levels, with a lower effect on phosphorylated Akt. In contrast, JNK1/2 phosphorylation was not affected. In addition, HMGB1 at 25 ng/ml significantly potentiated NF-κB activation in the presence of IL-1β.


CONCLUSIONS
Our results indicate that HMGB1 is overexpressed in OA synovium and mostly present in extracellular form. In OA synoviocytes, HMGB1 cooperates with IL-1β to amplify the inflammatory response leading to the production of a number of cytokines, chemokines and MMPs. Our data support a pro-inflammatory role for this protein contributing to synovitis and articular destruction in OA.
García-Arnandis
Isabel
I
Department of Pharmacology, University of Valencia, Valencia, Spain. isabelgarcia@hotmail.com
Guillén
Maria Isabel
MI
Gomar
Francisco
F
Pelletier
Jean-Pierre
JP
Martel-Pelletier
Johanne
J
Alcaraz
Maria José
MJ
D000368:Aged; D002478:Cells, Cultured; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D005260:Female; D024243:HMGB1 Protein / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D053583:Interleukin-1beta / Q000276:immunology* / Q000494:pharmacology; D020935:MAP Kinase Signaling System / Q000187:drug effects / Q000276:immunology; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000235:genetics / Q000378:metabolism; D053509:Matrix Metalloproteinase 13 / Q000235:genetics / Q000378:metabolism; D019278:Matrix Metalloproteinase 3 / Q000235:genetics / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D020370:Osteoarthritis, Knee / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D013583:Synovial Membrane / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
D024243:HMGB1 Protein; D053583:Interleukin-1beta; D016328:NF-kappa B; D012333:RNA, Messenger; D051057:Proto-Oncogene Proteins c-akt; D048049:Extracellular Signal-Regulated MAP Kinases; D048051:p38 Mitogen-Activated Protein Kinases; D053509:Matrix Metalloproteinase 13; D019278:Matrix Metalloproteinase 3; D020781:Matrix Metalloproteinase 1
J Clin Endocrinol Metab. 2005 Aug;90(8):4710-5
15914533
J Leukoc Biol. 2009 Sep;86(3):617-23
19401391
Mol Cell Biol. 2007 Aug;27(16):5650-63
17548469
Curr Opin Clin Nutr Metab Care. 2000 May;3(3):205-11
10871236
Invest Ophthalmol Vis Sci. 2003 Dec;44(12):5182-8
14638715
Ann Rheum Dis. 1999 May;58(5):297-302
10225815
Biochem Soc Symp. 2003;(70):115-23
14587287
Ann Rheum Dis. 2005 Jun;64(6):891-8
15498796
Arthritis Rheum. 2003 Aug;48(8):2173-7
12905470
J Biol Chem. 2008 May 23;283(21):14221-9
18332138
Rheumatology (Oxford). 2010 May;49(5):854-61
20110250
J Immunol. 2003 Dec 1;171(11):6080-9
14634122
J Immunol. 2005 Jun 15;174(12):7506-15
15944249
Arthritis Rheum. 1985 May;28(5):554-61
2988573
Cytokine Growth Factor Rev. 2003 Oct;14(5):409-26
12948524
Rheumatology (Oxford). 2006 Oct;45(10):1201-9
16571608
Clin Immunol. 2005 May;115(2):118-28
15885632
J Exp Med. 2000 Aug 21;192(4):565-70
10952726
J Leukoc Biol. 2007 Jan;81(1):84-91
17035340
Cytokine. 2000 Oct;12(10):1469-79
11023661
Antioxid Redox Signal. 2007 Nov;9(11):1979-89
17949278
Arthritis Res Ther. 2006;8(6):R187
17177994
J Leukoc Biol. 2009 Sep;86(3):655-62
19564572
N Engl J Med. 1997 Apr 10;336(15):1066-71
9091804
Oncogene. 1996 Sep 19;13(6):1323-33
8808707
J Biol Chem. 1995 Jul 14;270(28):16483-6
7622446
J Leukoc Biol. 2007 Jan;81(1):49-58
16980512
Angiogenesis. 2008;11(1):91-9
18264787
Biochim Biophys Acta. 2007 Mar;1773(3):309-20
17208315
Arthritis Rheum. 2005 Aug;52(8):2376-85
16052547
J Clin Invest. 1997 Apr 1;99(7):1534-45
9119997
Arthritis Rheum. 2001 Jul;44(7):1555-67
11465707
J Cell Biol. 2007 Oct 8;179(1):33-40
17923528
Gut. 2002 Dec;51(6):818-26
12427784
J Biol Chem. 1998 Mar 27;273(13):7620-7
9516466
Arthritis Rheum. 1999 Apr;42(4):609-21
10211874
Arthritis Rheum. 1986 Aug;29(8):1039-49
3741515
Biochem J. 1987 Nov 15;248(1):265-8
2829822
Osteoarthritis Cartilage. 2004 May;12(5):409-18
15094140
Arthritis Rheum. 1998 Nov;41(11):1987-94
9811054
J Rheumatol. 2007 Mar;34(3):523-33
17295438
Arthritis Res. 2001;3(2):118-26
11178119
J Immunol. 1991 Oct 1;147(7):2187-95
1918955
J Pathol. 2008 Mar;214(4):515-22
18200630
Arthritis Rheum. 2001 Jun;44(6):1237-47
11407681
Arthritis Rheum. 2004 Dec;50(12):3866-77
15593223
J Intern Med. 2004 Mar;255(3):344-50
14871458
FEBS Lett. 2000 Jan 7;465(1):23-7
10620700
Clin Exp Rheumatol. 2007 Sep-Oct;25(5):740-2
18078623
J Biol Chem. 1998 Sep 18;273(38):24832-8
9733787
Arthritis Res Ther. 2008;10(3):209
18598385
Osteoarthritis Cartilage. 2008 Jul;16(7):749-55
18164633
Arthritis Rheum. 1993 Jun;36(6):762-71
8507217
J Immunol. 2008 Feb 15;180(4):2531-7
18250463
Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1181-6
19139395
J Clin Invest. 1989 Feb;83(2):647-61
2783591
Arthritis Rheum. 2002 Aug;46(8):2087-94
12209513
Arthritis Res Ther. 2008;10(2):R33
18346273
Lab Invest. 2003 Apr;83(4):579-88
12695561
Arthritis Rheum. 2006 Jan;54(1):253-63
16385542
J Leukoc Biol. 2007 Mar;81(3):741-7
17135572
J Immunol. 2001 Nov 15;167(10):6015-20
11698482
J Immunol. 2008 Sep 15;181(6):4240-6
18768881
Mol Cell Biol. 1993 Nov;13(11):7191-8
8413306